Phase 2 clinical study of neoadjuvant chemotherapy for HER2-negative primary breast cancer patients using dose dense nab-paclitaxel followed by dose dense Epirubicin and cyclophosphamide
Not Applicable
- Conditions
- HER2 negative primary breast cancer
- Registration Number
- JPRN-UMIN000019787
- Lead Sponsor
- Dept of breast oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) HER2 positivity 2) Previous incident of severe complication 3) Previous incident of institutional pneumonia 4) Previous incident of drug allergy 5) Active status of other cancers 6) Inflammatory breast cancer 7) Possible pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method